| Title |
Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib
|
|---|---|
| Published in |
OncoTargets and therapy, September 2013
|
| DOI | 10.2147/ott.s30748 |
| Pubmed ID | |
| Authors |
Heather M Shaw, Marcia Hall |
| Abstract |
Olaparib has shown promising anticancer activity as a single agent in the treatment and maintenance of recurrent ovarian cancer in early clinical trials, but it is far from standard therapy. This article outlines the problem of relapsed ovarian cancer and the mechanisms of poly(ADP-ribose) polymerase inhibitors and reviews the recent literature pertaining to olaparib in ovarian cancer. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 39 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Ecuador | 2 | 5% |
| United States | 1 | 3% |
| Colombia | 1 | 3% |
| Unknown | 35 | 90% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 9 | 23% |
| Student > Bachelor | 4 | 10% |
| Unspecified | 3 | 8% |
| Professor | 3 | 8% |
| Lecturer | 3 | 8% |
| Other | 10 | 26% |
| Unknown | 7 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 14 | 36% |
| Agricultural and Biological Sciences | 9 | 23% |
| Unspecified | 3 | 8% |
| Nursing and Health Professions | 1 | 3% |
| Immunology and Microbiology | 1 | 3% |
| Other | 5 | 13% |
| Unknown | 6 | 15% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 December 2013.
All research outputs
#20,823,121
of 25,584,565 outputs
Outputs from OncoTargets and therapy
#1,573
of 2,967 outputs
Outputs of similar age
#161,676
of 212,862 outputs
Outputs of similar age from OncoTargets and therapy
#23
of 30 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,967 research outputs from this source. They receive a mean Attention Score of 3.0. This one is in the 31st percentile – i.e., 31% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 212,862 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 10th percentile – i.e., 10% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 30 others from the same source and published within six weeks on either side of this one. This one is in the 10th percentile – i.e., 10% of its contemporaries scored the same or lower than it.